The company clocked impressive volume growth and robust operating performance in the December quarter, but a high level of ...

Brokerages praise UltraTech Cement's Q3 performance, foreseeing market share gains and future growth despite profit decline ...

Key aspects to monitor in the earnings report include the outlook for domestic demand and the trajectory of export growth, ...

Cipla's US sales are expected to be adversely impacted by price erosion and supply disruptions for tumor drug Lanreotide, ...

UltraTech Cement shares rose 1% following strong Q3 results, with a 17% YoY profit decline but revenue exceeding estimates.

Brokerages have reacted to the third-quarter financial results of UltraTech Cement Ltd., Dr. Reddy's Ltd. and Hindustan Petroleum Corporation Ltd. UltraTech remains a strong pick due to its solid ...

TCS and Infosys, which are both debt-free, will benefit from the weakening of the rupee because most of their revenue is in US dollars, says Moody’s.

Despite the decline in profit, the quarter 3 results exceeded Street expectations, with net profit surpassing the estimated ...

UltraTech share price in morning trades on Friday ,added to its gains of 6.8% seen on Thursday post Q3 results. Post a sequential uptick in profitability and firm volume outlook, analysts remain posit ...

Profit: Cement maker UltraTech Cement on Thursday reported more than 17 per cent decline in its consolidated net profit for Q3 FY25 at Rs 1,470 crore, compared to Rs 1,774.78 crore in the year-ago ...

Goldman Sachs reportedly has maintained a 'Buy' rating and increased its target price to Rs 12,580, up from Rs 12,460, citing volume recovery and lower costs contributing to margin improvement ...

Following Q3 earnings, UltraTech Cement remains top cement pick of several brokerages. They remain bullish on the stock given ...